StockData
OptimizeRx Corp logo

OptimizeRx Corp (OPRX) company profile

OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/3034% below fair value
$6.94+0.30 (+4.52%)

Close on Nov 17, 2026Market cap $130.72MP/E 28.9Yield –

About OptimizeRx

Services-Business Services, NEC, SIC 7389

OptimizeRx Corporation provides digital healthcare technology and marketing solutions for the life sciences sector. The company offers technology platforms that enable pharmaceutical manufacturers and marketing agencies to reach healthcare professionals and patients. Its core solutions include an artificial intelligence-driven Dynamic Audience Activation Platform, patent-protected Micro-Neighborhood Targeting, and audience profiling tools. It also delivers banner messaging through point-of-care networks, real-time pharmacy dispensing alerts, and financial copay messaging integrated directly into electronic health record systems and electronic prescribing platforms.

The company connects more than two million healthcare providers in the United States and millions of patients, serving over one hundred pharmaceutical manufacturer clients. Its workforce operates primarily remotely across the United States and Croatia, supported by technical contractors located in India, Ukraine, Croatia, and the United States. In addition, the firm conducts operations through a subsidiary in Croatia. OptimizeRx maintains its principal executive offices in Waltham, Massachusetts.

Summary of the business section of OptimizeRx's latest annual report, written by StockData.

Company profile

Company

Legal name
OptimizeRx Corp
Founded
2006
Headquarters
Waltham, MA
Address
260 Charles Street, Suite 302 02453
Phone
(248) 651-6558
Employees
104, Dec 31, 2025
Industry
Services-Business Services, NEC
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
UHY LLP, Sterling Heights, Michigan

Stock & identifiers

Ticker
OPRX
Exchange
Nasdaq
IPO date
Nov 28, 2007
Shares outstanding
19M, Jul 30, 2026
Public float
$240.86M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-3 reverse, May 14, 2018
SEC CIK
1448431
CUSIP
68401U204
ISIN
US68401U2042
FIGI
BBG000HKQH91
Share class FIGI
BBG001S999P1
EIN
26-1265381

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William J. FebboCEO, Director600,852
Andrew J. D'SilvaChief Business Officer99,246
Brendan W. MerrellCHIEF OPERATING OFFICER25,187
Edward StelmakhChief Finance & Strat Officer121,791
Stephen L. SilvestroChief Executive Officer262,751
Marion Odence-FordChief Legal & Admin Officer90,407
Theresa GrecoChief Commercial Officer71,954
Doug BeschChief Product & Tech Officer66,876
Mariyamma Varghese PrestiDirector13,060
Ellen O'Connor VosDirector135,159
Gregory D. WassonDirector91,700
James Paul LangDirector433,837
Patrick D. SpanglerDirector78,732
Cathy KlemaDirector56,137

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Stephen Silvestro
$2.72M$3.85M$1.53M$73–
FY2025
William Febbo
$0$0$1.53M$73–
FY2024$2.27M-$305.93K$991.22K$29–
FY2023$2.79M$2.30M$950.04K$85–
FY2022$694.40K-$7.30M$1.80M$54–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Stephen Silvestro
Chief Executive Officer
$500.00K$752.18K$834.31K$627.62K$3.60K$2.72M+179%
Edward Stelmakh
Chief Financial & Strategy Officer
$450.00K$252.19K$334.31K$471.87K$15.80K$1.52M+51%
Theresa Greco
Chief Commercial Officer
$367.50K$353.18K$409.31K$398.47K$15.80K$1.54M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 104 full-time employees and 1 part-time employee in the U.S, as well as 28 full-time employees in Croatia.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?